605 results about "Heart tissues" patented technology

The invention relates to the technical field of medical image processing, in particular to an engineered heart tissue pulsation trajectory automatic analysis method based on an image recognition algorithm, which comprises the following steps: S1, multi-modal image fusion: performing space-time registration and feature fusion on acquired multi-modal heart images to generate a fused image sequence; s2, cardiac muscle tissue segmentation: outputting a cardiac muscle tissue segmentation result with a timestamp; s3, motion track modeling: generating three-dimensional track point cloud data in a pulsation period; s4, feature parameter extraction: performing spatial-temporal feature analysis on the track point cloud data, and extracting multi-dimensional motion parameters; and S5, heterogeneity atlas generation: generating a cardiac pulse heterogeneity atlas according to the multi-dimensional motion parameters. According to the method, automatic analysis of the cardiac pulse track and generation of the heterogeneity atlas based on the multi-modal image and space-time modeling are realized, and the precision and the intelligent level of cardiac motion anomaly recognition are remarkably improved.

Embodiments of the invention include additional methods and compositions for fabricating organoids. A unique approach has been developed for the rapid aggregation of defined number of cells using a micropillar-based template to limit the size of organoids, which are then more commonly referred to as spheroids. This procedure can be utilized to create in vitro cardiac tissue models (e.g., cardiac organoids) simply, rapidly, and inexpensively. In certain aspects an alginate-gelatin based hydrogel premixed with cardiomyocytes is used in combination with a patterned microfluidic chip / cell culture chamber having an array of micropillars to fabricate 3D cardiac organoids.

System and methods are described for developing a delivery plan for a pulsed field ablation device for treating an arrhythmia. A method runs a lesion development simulation based on cardiac characteristics and a treatment plan that specifies a delivery plan and a target location to generate a simulated lesion having lesion characteristics. The method initializes a three-dimensional (3D) mesh representing a heart based on cardiac characteristics. The vertices of the 3D mesh are associated with cardiac tissue characteristics with some of the associated with cardiac tissue characteristics representing an arrhythmia source. The method adjusts the cardiac tissue characteristics of vertices of the 3D mesh to reflect the effect of an ablation resulting in formation of the simulated lesion. The method runs a lesion evaluation simulation based on the 3D mesh with the adjusted cardiac tissue characteristics to determine whether the simulated lesion would be effective at treating the arrhythmia.

The invention provides a free breathing heart fat fraction and multi-relaxation parameter simultaneous quantitative magnetic resonance imaging method, a free breathing heart fat fraction and multi-relaxation parameter simultaneous quantitative magnetic resonance imaging device, a terminal and a medium. The method comprises the following steps: scanning a plurality of imaging layers on heart tissues of a detected object in a free breathing state to obtain a double-echo image of each cardiac cycle corresponding to each imaging layer and an electrocardio trigger signal; simulating an evolution process of a magnetization vector based on a Bloch equation and an electrocardio trigger signal, and establishing a dictionary; on the basis of the double-echo image after image processing, water-fat separation operation based on mixed multi-echo is executed, and a water signal image and a fat fraction graph are obtained; and obtaining a relaxation parameter group diagram of the detected object in a mode of matching the water signal image with the dictionary. Collection is carried out when the detected object freely breathes, the burden of the detected object is relieved, and the fat fraction quantification precision and the water-fat separation accuracy are guaranteed.

Coaptation assist device for repairing cardiac valves and associated systems and methods are disclosed herein. A coaptation assist device configured in accordance with embodiments of the present technology can include, for example, a fixation member configured to press against cardiac tissue proximate to a native valve annulus, and a stationary coaptation structure extending away from the fixation member. The coaptation structure can include an anterior surface configured to coapt with a first native leaflet during systole and a posterior surface configured to displace at least a portion of a second native leaflet. The device also includes at least one sensor configured to detect parameters associated with at least one of cardiac function and device functionality. The sensors can be pressure sensors configured to detect left atrial pressure and / or left ventricular pressure.

A method for ablating tissue by applying at least one pulse train of pulsed-field energy. The method includes delivering a pulse train of energy having a predetermined frequency to cardiac tissue, the pulse train including at least 60 pulses, an inter-phase delay between 0 μs and 5 μs, an inter-pulse delay of at least 5 μs, and a pulse width of 5 μs.

Apparatuses, systems, and methods for various devices, such as prosthetic valves. Some examples are directed to improvements in anchoring at a native heart valve, which may reduce possible trauma to a treatment or implantation site. Compliant and flexible anchoring features and methods are disclosed to reduce force upon a treatment or implantation site including heart tissue that surrounds leaflets of a mitral or tricuspid valve. Improved mechanisms for deployment of devices including motorized methods are also disclosed.

A method for ablating tissue by applying at least one pulse train of pulsed-field energy. The method includes delivering a pulse train of energy having a predetermined frequency to cardiac tissue, the pulse train including at least 60 pulses, an inter-phase delay between 0 μs and 5 μs, an inter-pulse delay of at least 5 μs, and a pulse width of 5 μs.

A catheter includes: (a) a shaft for insertion into a heart of a patient, (b) an expandable distal-end assembly, which is coupled to the shaft and is configured to make contact with tissue of the heart, (c) at least first and second electrocardiogram (ECG) electrodes, which are coupled to an outer surface of the expandable distal-end assembly, and when placed in contact with the tissue, are configured to sense ECG signals in the tissue, and (d) a reference electrode, which is positioned within an inner volume of the distal-end assembly, and in an expanded position of the distal-end assembly, the reference electrode: (i) has no physical contact with the tissue, and (ii) is positioned at a first distance from the first ECG electrode and at a second distance from the second ECG electrode, and the difference between the first and second distances is smaller than a predefined threshold.

The wire comprises an insulating layer, an electrode tip assembly and an anchoring component, the electrode tip assembly comprises an operating part and an electrode tip, the electrode tip is arranged at the far end of the operating part, and the electrode tip assembly can move between a first position and a second position relative to the insulating layer; the electrode tip assembly at the first position is located in the insulating layer, the electrode tip of the electrode tip assembly at the second position extends out of the insulating layer, the surface of the electrode tip is not smooth, and the area of the minimum cross section of the electrode tip is 4.0 mm < 2 >. According to the lead for pace-making, the electrode tip is provided with the non-smooth surface, so that the electrode tip can be slowly inserted into ventricular septal myocardial tissue even if a conical structure is not adopted, and is easy to screw in. The arrangement can ensure that the cross section is not similar to a conical structure and has a small-area cross section, the cross section is not easy to break when being inserted into heart tissue, and the cross section area is small, so that the damage to normal myocardium when the lead is pulled out is small.

The invention belongs to the technical field of biological medicines, and particularly relates to application of oxibenzophenone in preparation of a medicine for treating pathological cardiac hypertrophy and / or heart failure. Research results in myocardial cells of primary newborn rats show that Exibenzophenone can inhibit pathological hypertrophy of myocardial cells induced by phenylephrine (PE). Animal experiments show that the epoxybenzophenone can improve cardiac dysfunction induced by aortic arch constriction (TAC) and reduce cardiac hypertrophy and cardiac tissue fibrosis. The invention provides a new drug research and development approach and a drug action target for treating pathological cardiac hypertrophy and heart failure, and has very important medicinal value.

The invention belongs to the technical field of biology, and particularly relates to a construction method and application of a Car4 gene tracing animal model based on CRISPR / Cas9. According to the invention, an EGFP-CreERT2 gene knock-in mouse controlled by a Car4 gene is constructed in a gene insertion manner. While expressing the CA4 protein, the mouse also expresses fusion protein of EGFP (Enhanced Green Fluorescent Protein), a ligand binding region mutant (ERT) of an estrogen receptor and Cre recombinase. When the gene is knocked into a mouse, the EGFP can well play a role in tracing the CA4 protein; the insertion of the EGFP and CreERT2 genes does not have obvious influence on the expression and function of CA4 in cardiac muscle tissues; when the gene is inserted into a mouse to realize CA4 protein tracing, a reliable Cre tool mouse is provided for realizing conditional knockout of a target gene in capillary endothelial cells in heart tissues.

The invention relates to a CACNA1A-based mental patient heart death intelligent identification system and method, the system comprises an immunohistochemical staining device, an image acquisition unit, an image analysis unit and an intelligent identification unit, the immunohistochemical staining device is used for performing CACNA1A immunohistochemical staining on formalin-fixed paraffin-embedded heart tissue slices; the image acquisition unit is used for shooting and obtaining a heart tissue CACNA1A immunohistochemical staining image; the image analysis unit is used for processing the heart tissue CACNA1A immunohistochemical staining image so as to determine a tissue staining region and image features thereof; and the intelligent identification unit outputs an identification prediction result of heart death of the mental patient according to the image features of the tissue staining region. Compared with the prior art, the mental patient heart death identification system can intelligently and accurately identify mental patient heart death.

The title of the invention is "using blood conductivity to control cardiac ablation". Methods and systems provide lesion size assessment for ablation in tissue, such as cardiac tissue. The lesion size assessment is based on parameters including blood conductivity, hot spot temperature, catheter tip temperature, and current data of radio frequency (RF) ablation energy used, such as power, duration, temperature, irrigation, and contact force.

A transcatheter stent valve for heart valve replacement having a stent frame formed from a SE portion extending throughout the length of the stent frame and a BE portion extending lengthwise throughout and connected together in series around the circumference of the stent frame. The SE portion provides outward force against the annulus of the native heart tissues, the BE portion allows the perimeter to be adjusted to accommodate a large range of heart valve perimeters.

Systems and methods to process motion signals obtained from at least one motion sensor during delivery of plurality of PFA pulses or pacing signals to heart tissue location(s) and determine degrees of diaphragm spasm affected by the PFA or pacing signals. In some embodiments the system identifies reduction of diaphragm spasm during delivery of PFA pulses to a certain location and upon such identification indicates that continued delivery of further PFA pulses to that certain location may cause irreversible damage to the Phrenic nerve. Additionally, or alternatively, the system utilizes the diaphragm spasm degrees measured following pacing or ablation of at least two heart tissue locations, to map the degrees of spasm affected by the ablation of various heart tissue locations and thereby enables to conduct ablation at location associated with reduced spasm.

Embodiments of methods and systems for determining electrocardiogram (ECG) depth of electrical activity. Electrical activity from a plurality of electrodes of a catheter is received; and within the electrical activity, an electrical signal originating from a depth within cardiac tissue is identified. In some embodiments, spatial electrode signal analysis of the electrical activity may be performed for each electrode of the plurality of electrodes. In some embodiments, a linear and / or non-linear combination of signal components within the electrical activity may be calculated. In some embodiments, a neural network may be provided with the electrical signals and may determine an estimated distance to the nearest activation for at least one of the plurality of electrodes. A visualization of the identified electrical signals at a specified depth within the cardiac tissue may be provided for display.

The invention relates to the technical field of medical instruments, and discloses a method and application of intelligent cardiac pacemaker equipment based on biofeedback regulation, the intelligent cardiac pacemaker equipment based on biofeedback regulation comprises a shell, the interior of the shell is provided with a pulse generator, the pulse generator is used for conducting an electrical stimulation signal to cardiac tissue, and the pulse generator is connected with a cathode and an anode through a control module; the storage battery is mounted on one side in the shell and is used for supplying power to the pulse generator; the control module comprises an information acquisition module used for acquiring physiological information of a user in real time; the signal processing module is used for receiving and preprocessing the physiological signals; and the intelligent regulation and control module is combined with the output data of the signal processing module to regulate and control the working state of the pulse generator. By integrating the information acquisition module, the signal processing module and the intelligent regulation and control module, physiological information of a user is monitored in real time, and the working state of the pulse generator is accurately regulated, so that effective electrical stimulation on the heart is realized, and normal physiological rhythm of the heart is ensured.

The invention provides a free breathing heart multi-parameter simultaneous quantitative magnetic resonance imaging method and device, a terminal and a medium, and the method comprises the steps: carrying out the scanning of the heart tissue of a detected object in a free breathing state based on an established corresponding heart multi-parameter simultaneous quantitative magnetic resonance sequence, and obtaining a magnetic resonance scanning image; and processing to obtain a processed magnetic resonance scanning image. And matching the processed magnetic resonance scanning image with the established dictionary to obtain a parameter chart of the heart tissue of the detected object. By means of the method, the problems that in the prior art, T1, T2, T1 rho and other parameters of the heart tissue cannot be measured at the same time in the free breathing state, and the influence of a non-uniform B1 field on parameter measurement cannot be corrected at the same time can be solved.

A system for delivering pulsatile energy to cardiovascular tissue is provided. Aspects of the system include: a console assembly including a potential source; a manifold assembly operably connected to an output of the console assembly, where the manifold assembly includes an oscillator configured to generate pulsed energy from energy transmitted by the potential source; and a conduit assembly operably connected to the output end of the manifold assembly. The catheter assembly of the present invention comprises: a connector operably connecting the catheter assembly to a manifold assembly and configured to convert a first pulsed energy generated by the manifold assembly into a second pulsed energy; a catheter including a fluid channel operably connected to the output end of the connector and configured to transmit a second pulse energy; and a cardiac tissue compliant element configured to receive the second pulse energy transmitted through the fluid passage of the catheter to apply the pulsatile energy to the cardiovascular tissue. Also provided are methods for delivering pulsatile energy to cardiovascular tissue, e.g., deploying the system such that the heart tissue compliant element of the system is adjacent to the cardiovascular tissue, and engaging the system in such a manner that the heart tissue compliant element delivers energy to the cardiovascular tissue. In addition, provided are separate catheter assemblies as well as kits comprising components of the systems described herein. These systems, assemblies, methods, and kits can be used for a variety of different applications, including balloon angioplasty applications or other catheter-based therapies or treatments.

A non-invasive, passive, fully automated heart sound-based system and method is provided that provides estimation of blood velocity, tissue movement, and lumen size parameters for heart assessment. The system uses a computer processor and software to receive PCG acoustic signals from one or more sensors and simultaneously receive electrocardiogram (ECG) signals from one or more sensors attached to the patient. A phonocardiogram (PCG) processing system and method computes metrics of indices of echocardiogram parameters of heart tissue movement and valve blood flow for evaluation.

This disclosure relates to electro-anatomical mappings of cardiac tissue at different depths using a multi-electrode catheter. A multi-electrode catheter within a heart of a patient has a first plurality of electrodes on a first side and a second plurality of electrodes on a second side, wherein the first side is proximate to cardiac tissue at a first location and the second side is facing away from the cardiac tissue. Electrical activity is received from at least one electrode on the first side and the at least one electrode on the second side, and a signal analysis is performed thereon based at least in part on distances between electrodes on different sides of the multi-electrode catheter. The process is repeated for further locations of cardiac tissue in the heart, and an electro-anatomical map of the heart depicting electrical activity or scar tissue is generated based on the signal analysis.

Devices and methods for mapping tissue, such as cardiac tissue, and applying electrical energy to ablate the tissue may include an applicator region comprising two or more wire electrodes that extend between the arms of the device as well as a plurality of mapping and / or sensing electrodes (e.g., ring electrodes) on the arms and / or the elongate body. These devices may sense electrical activity using the mapping electrodes and may deliver energy between the first wire electrode and the second wire electrode to ablate, for example, cardiac tissue.

A system and method for performing virtual birefringence imaging and virtual staining (e.g., Congo red) of label-free human tissue is disclosed to show that a single trained neural network can rapidly transform autofluorescence images of label-free tissue into brightfield and polarized microscopy images, matching their histochemically-stained versions. Blind testing with quantitative metrics and pathologist evaluations on cardiac tissue showed that the virtually stained polarization and brightfield images highlight amyloid patterns in a consistent manner, mitigating challenges due to variations in chemical staining quality and manual imaging processes in the clinical workflow.

A device for implantation in a left atrial appendage of the heart comprises docking station comprising a radially expansible element that is adjustable between a contracted orientation suitable for transluminal delivery and a deployed orientation configured to anchor within the left atrial appendage and fluidically isolate the left atrial appendage from the left atrium, the docking station also includes a recessed socket accessible from the left atrium through an opening, and a closure coving the opening. A modular active element is configured for detachable engagement within the recessed socket of the docking station. The modular active element comprises a treatment element configured to electrically stimulate heart tissue, thermally stimulate heart tissue, electroporate heart tissue, or deliver a substance into heart tissue or a chamber of the heart, or a sensing element configured to detect a parameter selected from temperature, pressure, electrical signal, heart rate, or respiratory rate.

The invention provides a small nucleic acid composition, application of the small nucleic acid composition in preparation of a medicine and a product, and belongs to the technical field of biological medicine. The invention designs a small nucleic acid composition ASO133 / 7 / 142 / 30 containing four corresponding antisense oligonucleotide fragments aiming at four regions of miR-133, let-7, miR-142-3p and miR-30 seed sequences contained in a 3 '-terminal untranslated region sequence of ATP2A2 mRNA (messenger ribonucleic acid), and the small nucleic acid composition ASO133 / 7 / 142 / 30 has a nucleotide sequence as shown in SEQ ID NO. 1. By adopting the small nucleic acid composition provided by the invention, the expression level of ATP2A2 in HL-1 cells can be increased, and the expression level of ATP2A2 in heart tissues can be remarkably improved.

The invention discloses an application of hydroxygenkwanin (HGK) in preparation of a drug for preventing and treating cardiotoxicity induced by antitumor drugs. The method comprises the following steps: inducing doxorubicin (DOX), establishing a myocardial cell H9C2 injury model, and determining the DOX-induced myocardial cell injury minimum concentration; after 20 [mu] M of HGK is added into a treatment group, DOX-induced H9C2 cell apoptosis can be significantly improved. A mouse myocardial injury model is induced and established by DOX, and compared with a doxorubicin group, the left ventricular systolic fraction (FS%) and ejection fraction (EF%) of mice in the doxorubicin and hydroxygenkwanin group are remarkably increased, the myocardial fiber structure is improved, the cytoplasm vacuolation is reduced, the levels of serum cTnT, CK-MB and BNP are reduced, and the ROS level of heart tissue is reduced. Therefore, the hydroxygenkwanin can obviously reduce the cardiotoxicity induced by the DOX.

The invention relates to the field of biological medicine, in particular to application of S100A9 in treatment or detection of diabetic cardiomyopathy. The research finds that the expression of S100A9 in the heart tissue of a diabetic cardiomyopathy mouse is obviously increased. Overexpression of the S100A9 can aggravate myocardial injury and cardiac dysfunction, and inhibition of expression or activity of the S100A9 can improve illness conditions. Both the S100A9 inhibitor paquinimod and the macrophage scavenger chlorophosphonate liposome can reduce the concentration of S100A9 in serum, relieve cardiac enlargement and myocardial fibrosis and recover the left ventricular ejection fraction. In addition, the S100A9 can be used as a marker for detecting the diabetic cardiomyopathy, and related detection products can reflect the severity of the illness state by detecting the expression quantity of the S100A9 in tissue cells or body fluid. The invention provides a new target spot, medicine and detection means for treatment and detection of diabetic cardiomyopathy.

The technology disclosed herein relates to compositions and methods for improving the electrophysiological maturity of in vitro-differentiated cardiomyocytes. Media that promote electrophysiological maturation are described, as well as methods for the use of such media and the electrophysiologically matured cardiomyocytes in e.g., transplant and regenerative medicine procedures. The technology described herein is directed to cardiomyocyte maturation medium. Also described herein are associated compositions, kits, and matured cardiomyocytes. The cardiomyocyte maturation medium disclosed here can be used to modulate at least one electrophysiologic property of a cardiomyocyte. The electrophysiologically matured cardiomyocytes can engraft into cardiac tissue and can reduce or inhibit engraftment arrythmia in a subject.

Systems, catheter and methods for treating Atrial Fibrillation (AF) are provided, which are configure to illuminate a heart tissue having a lesion site; obtain a mitochondrial nicotinamide adenine dinucleotide hydrogen (NADH) fluorescence intensity from the illuminated heart tissue along a first line across the lesion site; create a 2-dimensional (2D) map of the depth of the lesion site along the first line based on the NADH fluorescence intensity; and determine a depth of the lesion site at a selected point along the first line from the 2D map, wherein a lower NADH fluorescence intensity corresponds to a greater depth in the lesion site and a higher NADH fluorescence intensity corresponds to an unablated tissue. The process may be repeated to create a 3 dimensional map of the depth of the lesion.